menu search

Tg therapeutics: things are stacking up against briumvi

TG Therapeutics, Inc. stock has declined by 75% since its approval highs, with little hope of recovery. The company's fortunes have been tied to its e...

October 16, 2023, 4:47 pm

Tg therapeutics: racing against time while their differentiators are still relevant

TG Therapeutics has transitioned from a developer of oncology drugs to a commercial-stage neurology company with the approval of its multiple sclerosi...

October 3, 2023, 2:26 pm

Why is tg therapeutics (tgtx) stock down 50% today?

Following a disappointing outcome for the second quarter, shares of biotechnology firm TG Therapeutics (NASDAQ: TGTX ) suffered a catastrophic loss. S...

August 1, 2023, 12:56 pm

Tg therapeutics: addressing the sc ocrevus concern

The launch of briumvi is off to a solid start, but the stock pulled back recently and fell more after R...

July 29, 2023, 9:50 pm

Ocrevus challenges briumvi: a closer look at tg therapeutics' position

TG Therapeutics, Inc.'s Briumvi, a treatment for multiple sclerosis, faces competition from Roche's Ocrevus, which has shown positive results in a Pha...

July 13, 2023, 5:49 pm

Tg therapeutics: recent progress of briumvi builds up momentum

Partial sales of TG Therapeutics, Inc.'s briumvi for Relapsing forms of multiple sclerosis reached $7.8...

July 5, 2023, 7:06 pm

Tg therapeutics: a buy for its monster multiple sclerosis agent

New earning asset briumvi launched in February and got approved in Europe. ...

June 15, 2023, 3:33 am

Tg therapeutics announces presentation of data from the ultimate i & ii phase 3 trials of briumvi® (ublituximab-xiiy) in multiple sclerosis at the 2023 consortium of multiple sclerosis centers annual

NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II P...

June 2, 2023, 1:15 pm

Tg therapeutics announces data from the ultimate i & ii phase 3 trials of briumvi® (ublituximab-xiiy) in multiple sclerosis to be presented at the 2023 consortium of multiple sclerosis centers annual

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the details of an upcoming oral presentation, highli...

May 31, 2023, 11:30 am

Why shares of tg therapeutics soared on tuesday

The company launched multiple sclerosis drug briumvi on Jan. 26. The drug reportedly has already had ne...

April 11, 2023, 1:49 pm

Top-notch biotech tg therapeutics logs 'solid jump' in sales; shares rocket

TG Therapeutics' new MS drug, Briumvi, experienced a "solid jump" in March sales, according to a report. TGTX stock flew on Monday....

April 10, 2023, 1:23 pm

Tg therapeutics announces positive chmp opinion for briumvi™ (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis in adults

NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Committee for Medicinal Products for Huma...

March 31, 2023, 11:30 am

Tg therapeutics: that icer report doesn't bother me

ICER published a report saying TG Therapeutics, Inc.'s briumvi is overpriced. It has said this for othe...

March 20, 2023, 1:25 pm

Tg therapeutics: strategy after briumvi launch

After a year of churn and doldrums, TG Therapeutics, Inc. finally got approval for, and launched, briumvi ...

February 1, 2023, 12:22 pm

Tg therapeutics: ramifications of briumvi approval

TG Therapeutics, Inc. is set to launch briumvi with an experienced in-house team. There are several fac...

January 2, 2023, 1:04 pm

Tg therapeutics (tgtx) gets fda nod for multiple sclerosis drug

The FDA approves TG Therapeutics' (TGTX) briumvi (ublituximab-xiiy) for treating relapsing forms of mul...

December 29, 2022, 12:02 pm

Tg therapeutics announces fda approval of briumvi™ (ublituximab-xiiy)

briumvi is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms ...

December 28, 2022, 6:48 pm

Tg therapeutics: ublituximab could achieve $1 billion in annual sales by year-end 2024

TG Therapeutics is approaching its Prescription Drug User Fee Act (PDUFA) goal date of December 28, 2022, for ublituximab for the treatment of relapsi...

December 15, 2022, 2:04 pm


Search within

Pages Search Results: